S1R is considered to be a potential drug target for treatment of neurodegenerative disorders and cancer (Herrando-Grabulosa et al., 2021; Kim and Maher, 2017; Ryskamp et al., 2019). The gene discussed is TMBIM4; the disease is cancer.